Literature DB >> 31501972

[Anti-p200 pemphigoid: clinical, diagnostic and therapeutic aspects].

Katharina Antonia Drerup1, Ulrike Wehkamp2.   

Abstract

Anti-p200 pemphigoid is a rare autoimmune blistering dermatosis. The clinical course is heterogeneous. Typically, immunoglobulin G (IgG) antibodies are found on the floor of salt-split skin, which differentiates p200 pemphigoid from bullous pemphigoid. It is necessary to perform immunoblotting and enzyme-linked immunosorbent assays (ELISA) to confirm the diagnosis. Small amounts of dapsone are often sufficient for disease control. The clinical and diagnostic characteristics of anti-p200 pemphigoid and the principles of treatment are presented exemplified by two case reports.

Entities:  

Keywords:  Autoimmune bullous disease; Dapsone; Enzyme-linked immunosorbent assay; Immunoblotting; Immunoglobulin G autoantibodies

Mesh：

Substances：

Year:  2020        PMID： 31501972     DOI： 10.1007/s00105-019-04478-1

Source DB:  PubMed          Journal:  Hautarzt        ISSN： 0017-8470            Impact factor:   0.751


  8 in total

1.  S2k guidelines for the treatment of pemphigus vulgaris/foliaceus and bullous pemphigoid.

Authors:  Rüdiger Eming; Michael Sticherling; Silke C Hofmann; Nicolas Hunzelmann; Johannes S Kern; Harald Kramer; Christiane Pfeiffer; Volker Schuster; Detlef Zillikens; Matthias Goebeler; Michael Hertl; Alexander Nast; Hans-Dieter Orzechowski; Miklós Sárdy; Enno Schmidt; Cassian Sitaru; Birte Sporbeck; Margitta Worm
Journal:  J Dtsch Dermatol Ges       Date:  2015-08       Impact factor: 5.584

Review 2.  Anti-p200 pemphigoid.

Authors:  Stephanie Goletz; Takashi Hashimoto; Detlef Zillikens; Enno Schmidt
Journal:  J Am Acad Dermatol       Date:  2014-04-24       Impact factor: 11.527

3.  [Anti-p200 pemphigoid: Remission under mycophenolate mofetil (Cellcept®)].

Authors:  D Raffin; M Delaplace; A Roussel; E Estève
Journal:  Ann Dermatol Venereol       Date:  2013-08-13       Impact factor: 0.777

Review 4.  [Anti-p200 pemphigoid].

Authors:  M M Holtsche; S Goletz; D Zillikens
Journal:  Hautarzt       Date:  2019-04       Impact factor: 0.751

5.  A novel subepidermal blistering disease with autoantibodies to a 200-kDa antigen of the basement membrane zone.

Authors:  D Zillikens; Y Kawahara; A Ishiko; H Shimizu; J Mayer; C V Rank; Z Liu; G J Giudice; H H Tran; M P Marinkovich; E B Bröcker; T Hashimoto
Journal:  J Invest Dermatol       Date:  1996-03       Impact factor: 8.551

6.  Clinical and immunological features and outcome of anti-p200 pemphigoid.

Authors:  M-H Commin; E Schmidt; S Duvert-Lehembre; A Lasek; C Morice; J-L Estival; S Debarbieux; E Rigal; C Pauwels; J De Quatrebarbes; A Roussel; E Goujon; P-E Stoebner; F Jouen; P Joly
Journal:  Br J Dermatol       Date:  2016-08-24       Impact factor: 9.302

7.  Histopathology of anti-p200 pemphigoid.

Authors:  Christian Rose; Wolfgang Weyers; Natalja Denisjuk; Uwe Hillen; Detlef Zillikens; Iakov Shimanovich
Journal:  Am J Dermatopathol       Date:  2007-04       Impact factor: 1.533

8.  Anti-laminin gamma-1 pemphigoid.

Authors:  Teruki Dainichi; Sadamu Kurono; Bungo Ohyama; Norito Ishii; Noriko Sanzen; Maria Hayashi; Chisei Shimono; Yukimasa Taniguchi; Hiroshi Koga; Tadashi Karashima; Shinichiro Yasumoto; Detlef Zillikens; Kiyotoshi Sekiguchi; Takashi Hashimoto
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-05       Impact factor: 11.205
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.